"The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics ( NASDAQ:VKTX ) is carving out a strong position with its dual GLP-1/GIP agonist VK2735, which showed up to 15% weight loss in Phase 2 trials."
"This includes evaluations in obese adults and those with type 2 diabetes, as well as a maintenance dosing trial that started last month. Additionally, Viking's VK2809 for non-alcoholic steatohepatitis (NASH) delivered impressive Phase 2b data, with up to 75% of patients achieving disease resolution without fibrosis worsening. Updates posted last week confirmed 44% of treated patients saw both NASH resolution and fibrosis improvement."
"However, Novo Nordisk ( ) just escalated the competition by outbidding Pfizer ( ) with an unsolicited $9 billion offer for Metsera ( NASDAQ:MTSR ), a clinical-stage biotech focused on next-generation obesity treatments. The bid includes about $6.5 billion in upfront cash plus up to $2.5 billion in milestones, valuing Metsera at up to $77.75 per share - a 133% premium over prior levels."
The GLP-1 drug market has grown rapidly over four years, currently exceeding $100 billion and projected to surpass $150 billion by 2030. Viking Therapeutics advanced its dual GLP-1/GIP agonist VK2735 to Phase 3 after Phase 2 showed up to 15% weight loss. The VANQUISH program includes trials in obese adults, people with type 2 diabetes, and a maintenance dosing study. Viking's VK2809 for NASH produced Phase 2b results with up to 75% achieving disease resolution and 44% showing both NASH resolution and fibrosis improvement. Big Pharma competition intensified as Novo Nordisk outbid Pfizer with a $9 billion offer for Metsera.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]